SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001640334-20-002150
Filing Date
2020-08-14
Accepted
2020-08-14 16:02:01
Documents
44
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 6-K nymox_6k.htm 6-K 8624
2 EX-99.1 nymox_ex991.htm EX-99.1 306015
3 EX-99.2 nymox_ex992.htm EX-99.2 12103
4 EX-99.3 nymox_ex993.htm EX-99.3 11977
11 nymox_ex991img1.jpg GRAPHIC 5623
  Complete submission text file 0001640334-20-002150.txt   1692012

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT nymx-20200630.xml EX-101.INS 272464
6 XBRL TAXONOMY EXTENSION SCHEMA nymx-20200630.xsd EX-101.SCH 38318
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE nymx-20200630_lab.xml EX-101.LAB 152027
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nymx-20200630_cal.xml EX-101.CAL 31733
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nymx-20200630_pre.xml EX-101.PRE 122321
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nymx-20200630_def.xml EX-101.DEF 52315
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 201104901
SIC: 2835 In Vitro & In Vivo Diagnostic Substances